Jeffrey Glaser, MD
Pain Medicine · Encino, CANPI 1154357010
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by AbbVie at 50.3% of the total. Reporting peaked in 2022 at $44,740 and has fallen 82.6% since, to $7,784 in 2025. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 875 payments — averaging $188.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$83K
- Abbott$49K
- Biohaven Pharmaceuticals, Inc.$11K
- Biohaven Pharmaceutical Holding Company Ltd.$6K
- Boston Scientific$6K
- Nevro Corp.$3K
- plus $6K from 30 others
What the payments were for
- Consulting fees$28,81018%
- Speaking & faculty fees$96,74959%
- Travel & lodging$13,3978%
- Food & beverage$25,58416%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 132 | $82,759 |
| Abbott | 370 | $49,334 |
| Biohaven Pharmaceuticals, Inc. | 42 | $10,839 |
| Biohaven Pharmaceutical Holding Company Ltd. | 18 | $6,420 |
| Boston Scientific | 126 | $6,077 |
| Nevro Corp. | 45 | $3,372 |
| Vertiflex, Inc. | 20 | $1,806 |
| Nalu Medical, Inc. | 12 | $1,195 |
| Globus Medical | 8 | $488 |
| Amgen(2 entities) | 20 | $263 |
| Biotronik NRO, Inc. | 6 | $251 |
| Axsome Therapeutics, Inc. | 8 | $200 |
| Teva Pharmaceuticals USA, Inc. | 9 | $167 |
| Lilly USA, LLC | 5 | $133 |
| Scilex Pharmaceuticals Inc. | 6 | $105 |
| Pfizer | 4 | $103 |
| Stryker | 3 | $99 |
| Spinesmith Holdings, LLC | 2 | $83 |
| Arbor Pharmaceuticals, Inc. | 4 | $82 |
| Redhill Biopharma Inc. | 4 | $77 |
| Intersect ENT, Inc. | 1 | $74 |
| Assertio Therapeutics, Inc. | 4 | $68 |
| Medtronic | 4 | $63 |
| Relievant Medsystems, Inc. | 3 | $60 |
| Zyla Life Sciences, Inc. | 3 | $51 |
| Stimwave Technologies Incorporated | 2 | $48 |
| DJO, LLC | 2 | $47 |
| Azurity Pharmaceuticals, Inc. | 2 | $46 |
| Bioventus LLC | 1 | $45 |
| Forte Bio-pharma LLC | 1 | $43 |
| Shionogi Inc | 2 | $34 |
| IBSA Pharma Inc. | 2 | $34 |
| Impel Pharmaceuticals Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $21 |
| SPR Therapeutics, Inc | 1 | $19 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$70,855
- PROCLAIM$40,099
- QULIPTA$26,113
- NURTEC ODT$16,757
- Senza Spinal Cord Stimulation System$2,170
- SPECTRA WAVEWRITER$1,501
- Superion ISS$1,202
- Nalu Neurostimulation System$945
- Intracept$917
- ETERNA$754
- Proclaim IPG$649
- OCTRODE$510
- GENERAL PAIN MANAGEMENT$331
- Proclaim Family of SCS IPGs$313
- Senza$264
- SUPERION$154
- Superion Indirect Decompression System$148
- Prospera$135
- WaveWriter Alpha Prime 16$123
How this compares
$164,540 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dihydroergotamine Mesylate | 13 | $32,159 |
| Gabapentin | 478 | $3,990 |
| Duloxetine Hcl | 63 | $737 |
| Tramadol Hcl | 124 | $433 |
| Cephalexin | 58 | $364 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $278 |
| Celecoxib | 11 | $276 |
| Meloxicam | 129 | $270 |
| Methylprednisolone | 37 | $243 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 26 | $203 |
| Sumatriptan Succinate | 11 | $96 |
| Cyclobenzaprine Hcl | 21 | $91 |
| Trazodone Hcl | 11 | $33 |
| Metoprolol Succinate | 11 | $10 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Encino
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
- Samir ShethRoseville$356K
- Einar OttestadStanford$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.